Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes

Mi Jin Kim, Kwang Ha Yoo, Ji Hoon Kim, Young Tak Seo, Byung Wook Ha, Jang Hyun Kho, Young Goo Shin, Choon Hee Chung

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Pinitol (3-O-methyl-d-chiro-inositol) was identified in putative insulin mediator fractions that have hypoglycemic activity, and appears to mimic the act effects of insulin by acting downstream in the insulin signaling pathway. We evaluated the effect of pinitol therapy in type 2 diabetic patients who were poorly controlled with hypoglycemic drugs, such as sulfonylurea, metformin and/or insulin. Twenty type 2 diabetic patients were enrolled in our study. Fasting glucose, fasting c-peptide, total cholesterol, triglyceride, and HDL- and LDL-cholesterol were checked before and after a 12-week pinitol treatment (20 mg kg-1 day-1). All subjects continued their current medications during the study. Adipocytokines, such as adiponectin, leptin, free fatty acids, and c-reactive protein (CRP) were checked before and after pinitol treatment. After pinitol treatment, fasting glucose, post-prandial glucose levels, and hemoglobin A1c were significantly decreased (P < 0.05). Fasting serum adiponectin, leptin, free fatty acid, and CRP levels did not change after pinitol treatment. In the unresponsive group, serum c-peptide levels were higher than in the responsive group. Twelve weeks of pinitol treatment altered glucose metabolism, but not lipid profiles or adipocytokine levels, in type 2 diabetic patients. Additional research is needed to define the physiological and potential therapeutic effects of pinitol administration.

Original languageEnglish
Pages (from-to)S247-S251
JournalDiabetes Research and Clinical Practice
Volume77
Issue number3 SUPPL.
DOIs
Publication statusPublished - 2007 Sep 1

Fingerprint

Adipokines
Type 2 Diabetes Mellitus
Glucose
Fasting
Insulin
Adiponectin
Leptin
Nonesterified Fatty Acids
Hypoglycemic Agents
Therapeutics
Peptides
pinitol
Metformin
Therapeutic Uses
Inositol
Serum
Lipid Metabolism
LDL Cholesterol
HDL Cholesterol
Meals

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, Mi Jin ; Yoo, Kwang Ha ; Kim, Ji Hoon ; Seo, Young Tak ; Ha, Byung Wook ; Kho, Jang Hyun ; Shin, Young Goo ; Chung, Choon Hee. / Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. In: Diabetes Research and Clinical Practice. 2007 ; Vol. 77, No. 3 SUPPL. pp. S247-S251.
@article{63e092116be04c79a59ae5cd93c3d394,
title = "Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes",
abstract = "Pinitol (3-O-methyl-d-chiro-inositol) was identified in putative insulin mediator fractions that have hypoglycemic activity, and appears to mimic the act effects of insulin by acting downstream in the insulin signaling pathway. We evaluated the effect of pinitol therapy in type 2 diabetic patients who were poorly controlled with hypoglycemic drugs, such as sulfonylurea, metformin and/or insulin. Twenty type 2 diabetic patients were enrolled in our study. Fasting glucose, fasting c-peptide, total cholesterol, triglyceride, and HDL- and LDL-cholesterol were checked before and after a 12-week pinitol treatment (20 mg kg-1 day-1). All subjects continued their current medications during the study. Adipocytokines, such as adiponectin, leptin, free fatty acids, and c-reactive protein (CRP) were checked before and after pinitol treatment. After pinitol treatment, fasting glucose, post-prandial glucose levels, and hemoglobin A1c were significantly decreased (P < 0.05). Fasting serum adiponectin, leptin, free fatty acid, and CRP levels did not change after pinitol treatment. In the unresponsive group, serum c-peptide levels were higher than in the responsive group. Twelve weeks of pinitol treatment altered glucose metabolism, but not lipid profiles or adipocytokine levels, in type 2 diabetic patients. Additional research is needed to define the physiological and potential therapeutic effects of pinitol administration.",
author = "Kim, {Mi Jin} and Yoo, {Kwang Ha} and Kim, {Ji Hoon} and Seo, {Young Tak} and Ha, {Byung Wook} and Kho, {Jang Hyun} and Shin, {Young Goo} and Chung, {Choon Hee}",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.diabres.2007.01.066",
language = "English",
volume = "77",
pages = "S247--S251",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3 SUPPL.",

}

Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. / Kim, Mi Jin; Yoo, Kwang Ha; Kim, Ji Hoon; Seo, Young Tak; Ha, Byung Wook; Kho, Jang Hyun; Shin, Young Goo; Chung, Choon Hee.

In: Diabetes Research and Clinical Practice, Vol. 77, No. 3 SUPPL., 01.09.2007, p. S247-S251.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes

AU - Kim, Mi Jin

AU - Yoo, Kwang Ha

AU - Kim, Ji Hoon

AU - Seo, Young Tak

AU - Ha, Byung Wook

AU - Kho, Jang Hyun

AU - Shin, Young Goo

AU - Chung, Choon Hee

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Pinitol (3-O-methyl-d-chiro-inositol) was identified in putative insulin mediator fractions that have hypoglycemic activity, and appears to mimic the act effects of insulin by acting downstream in the insulin signaling pathway. We evaluated the effect of pinitol therapy in type 2 diabetic patients who were poorly controlled with hypoglycemic drugs, such as sulfonylurea, metformin and/or insulin. Twenty type 2 diabetic patients were enrolled in our study. Fasting glucose, fasting c-peptide, total cholesterol, triglyceride, and HDL- and LDL-cholesterol were checked before and after a 12-week pinitol treatment (20 mg kg-1 day-1). All subjects continued their current medications during the study. Adipocytokines, such as adiponectin, leptin, free fatty acids, and c-reactive protein (CRP) were checked before and after pinitol treatment. After pinitol treatment, fasting glucose, post-prandial glucose levels, and hemoglobin A1c were significantly decreased (P < 0.05). Fasting serum adiponectin, leptin, free fatty acid, and CRP levels did not change after pinitol treatment. In the unresponsive group, serum c-peptide levels were higher than in the responsive group. Twelve weeks of pinitol treatment altered glucose metabolism, but not lipid profiles or adipocytokine levels, in type 2 diabetic patients. Additional research is needed to define the physiological and potential therapeutic effects of pinitol administration.

AB - Pinitol (3-O-methyl-d-chiro-inositol) was identified in putative insulin mediator fractions that have hypoglycemic activity, and appears to mimic the act effects of insulin by acting downstream in the insulin signaling pathway. We evaluated the effect of pinitol therapy in type 2 diabetic patients who were poorly controlled with hypoglycemic drugs, such as sulfonylurea, metformin and/or insulin. Twenty type 2 diabetic patients were enrolled in our study. Fasting glucose, fasting c-peptide, total cholesterol, triglyceride, and HDL- and LDL-cholesterol were checked before and after a 12-week pinitol treatment (20 mg kg-1 day-1). All subjects continued their current medications during the study. Adipocytokines, such as adiponectin, leptin, free fatty acids, and c-reactive protein (CRP) were checked before and after pinitol treatment. After pinitol treatment, fasting glucose, post-prandial glucose levels, and hemoglobin A1c were significantly decreased (P < 0.05). Fasting serum adiponectin, leptin, free fatty acid, and CRP levels did not change after pinitol treatment. In the unresponsive group, serum c-peptide levels were higher than in the responsive group. Twelve weeks of pinitol treatment altered glucose metabolism, but not lipid profiles or adipocytokine levels, in type 2 diabetic patients. Additional research is needed to define the physiological and potential therapeutic effects of pinitol administration.

UR - http://www.scopus.com/inward/record.url?scp=34547700332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547700332&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2007.01.066

DO - 10.1016/j.diabres.2007.01.066

M3 - Article

C2 - 17467106

AN - SCOPUS:34547700332

VL - 77

SP - S247-S251

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3 SUPPL.

ER -